While this retrospective study has limitations due to a small patient numbers and the paucity of experiments investigating the mechanistic insights of TEX-mediated effects, its merit lies in the demonstration that serial monitoring of the exosome cargo in patients' plasma during the delivery of anti-cancer therapy informs about the therapy-induced changes in the tumor and hence about outcome. Here, TEX46 is linked to neoplasm.